NVO Novo Nordisk A/S
Company Analysis
Latest News
🟢 NVO is trading 4.7% up today after legal win against unapproved Ozempic copies
NVO is trading 4.7% up at $49.65 in after-hours trading after Novo Nordisk secured a South African High Court order halting sales of unapproved Ozempic and...
Novo Nordisk halts South African sales of unapproved Ozempic, Wegovy copies
Novo Nordisk secured a High Court interim order in South Africa to halt the sale of unapproved weight-loss drugs. The ruling prevents local pharmacy group...
🟢 Novo Nordisk A/S extends move to 5.1% up
NVO is trading at $45.40, up 5.1% versus the comparison close of $43.19 during regular trading. This is a price-movement alert; no separate company-specific...
Novo Nordisk expects generic semaglutide in China by 2027, as protections end
Novo Nordisk expects generic versions of semaglutide to enter the Chinese market in the second quarter of 2027. CEO Mike Doustdar announced the timeline during...
Novo Nordisk Foundation launches $69M hub, accelerating European obesity drug discovery
The Novo Nordisk Foundation is launching CardioMetabolic Bridge, a pan-European initiative to accelerate drug discovery for obesity and type 2 diabetes. The...
🟢 Novo Nordisk A/S is trading 4.3% up today on plans to seek Chinese approval for oral Wegovy
Novo Nordisk A/S is trading 4.3% up at $45.41 following reports that the company plans to seek Chinese regulatory approval for an oral version of its...
Novo Nordisk seeks China approval for oral Wegovy, challenging Eli Lilly
Novo Nordisk plans to submit its oral version of the weight-loss drug Wegovy for regulatory approval in China. CEO Mike Doustdar announced on June 16 that the...
Novo Nordisk Wins UK Approval for Oral Wegovy, First in Europe
The UK Medicines and Healthcare products Regulatory Agency (MHRA) approved Novo Nordisk’s daily oral version of its weight-loss drug, Wegovy. This...
Novo Nordisk draws 10,000 UK sign-ups for oral Wegovy, expanding the market
Novo Nordisk’s oral version of Wegovy attracted over 10,000 people to a waiting list at UK pharmacy Chemist4U. This high interest signals strong demand for a...
🟢 Novo Nordisk A/S is trading 4.3% up today as investors reassess obesity drug trial data
Novo Nordisk A/S is trading 4.3% up today at $43.99 as investors provide a more constructive reassessment of recent obesity drug trial data. • The stock is...
Novo Nordisk Shares Slide, Despite Amycretin Delivering 14.6% Weight Loss
Novo Nordisk presented Phase 2 trial data for its investigational drug amycretin at the American Diabetes Association's 2026 Scientific Sessions. The...
🔴 Novo Nordisk A/S is trading 4% down today as market re-evaluates Ozempic vs. Mounjaro competition
Novo Nordisk A/S is trading 4% down at $41.24 as investors react to fresh data comparing Ozempic and Eli Lilly’s Mounjaro in type 2 diabetes. • Real-world...
Novo Nordisk says Ozempic matches Mounjaro, citing superior weight loss data
Novo Nordisk released real-world data comparing Ozempic to Eli Lilly’s Mounjaro for type 2 diabetes. The study analyzed patients already taking a 1 mg dose of...
Novo Nordisk reports CagriSema outperforms semaglutide in weight loss, hitting goals
Novo Nordisk presented positive REIMAGINE 1-3 Phase 3 trial results for CagriSema at the American Diabetes Association’s 2026 Scientific Sessions. The trials...
Employers Slash Wegovy Coverage, Citing Surging Healthcare Costs
U.S. employers are limiting or eliminating insurance coverage for GLP-1 weight-loss drugs like Novo Nordisk's Wegovy. Surging medication prices have created...
Novo Nordisk wins EU backing for oral Wegovy, expanding weight-loss options
Novo Nordisk’s oral semaglutide tablet received a positive opinion from the European Medicines Agency’s CHMP on June 5, 2026. The recommendation includes four...
🟢 Novo Nordisk A/S is trading 5.3% up today on sector enthusiasm and new clinical trial supply agreement
Novo Nordisk A/S is trading 5.3% up at $44.23 today, buoyed by positive sentiment in the weight-loss drug sector and a new company-specific development. •...
🟢 Novo Nordisk A/S is trading 4.5% up today on UAE launch of oral Wegovy pill
Novo Nordisk A/S is trading 4.5% up today at $43.88 following the launch of its oral Wegovy pill in the UAE, marking the first market outside the U.S. for this...
Novo Nordisk launches Wegovy pill in UAE, first market outside U.S.
Novo Nordisk launched the oral Wegovy pill in the United Arab Emirates on June 3, 2026. The UAE is the first country outside the United States to offer the...
🔴 Novo Nordisk A/S is trading 3% down today on renewed obesity-drug competition concerns
Novo Nordisk A/S is trading 3% down today at $44.20 as investors reassess long-term competitive dynamics in the obesity-drug market. • The decline follows...